Group 1 - MSCI announced the results of the November index review, with adjustments effective after the market close on November 24 [1] - The MSCI Global Small Cap Index will include 22 new stocks, such as Gilead Sciences (01672) and Meili Tianyuan Healthcare (02373) [1] - 17 stocks will be removed from the MSCI Global Small Cap Index, including China Gold International (02099) and China Nonferrous Mining (01258) [1] Group 2 - The MSCI Hong Kong Index will add 7 new stocks, including Chow Sang Sang (00116) and MGM China (02282) [2] - Stocks removed from the MSCI Hong Kong Index include Kintor Pharmaceutical (02171) and HKT Trust (00215) [2][3]

Group 1 - MSCI announced the results of the November index review, with adjustments effective after the market close on November 24 [1] - A total of 22 stocks were added to the MSCI Global Small Cap Index, including companies such as Genscript Biotech (01672) and Youzan (08083) [1] - 17 stocks were removed from the MSCI Global Small Cap Index, including China Gold International (02099) and Longi Green Energy (601869) [1] Group 2 - The MSCI Hong Kong Index included 7 new stocks, such as Chow Sang Sang (00116) and MGM China (02282) [2] - The MSCI Hong Kong Index removed stocks like Kintor Pharmaceutical (02171) and HKT Trust (00215) [2][3]

歌礼制药-B(01672)发布公告，于2025年11月5日，公司斥资约92.40万港元回购10万股股份，每股回购价 9.1-9.32港元。 ...

Group 1 - Company repurchased 100,000 shares at a cost of HKD 924,000 on November 5 [1] - The repurchase is part of the company's strategy to manage its capital and enhance shareholder value [1] - The company is preparing for the complete analysis of the ASC30 oral tablet Phase Ib study at the 2025 ObesityWeek® [1] Group 2 - The company is also conducting Phase Ib studies for ASC30 injection and preclinical studies for ASC31 and ASC47 combination therapy [1]

智通财经APP讯，歌礼制药-B(01672)发布公告，于2025年11月5日，公司斥资约92.40万港元回购10万股 股份，每股回购价9.1-9.32港元。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 歌禮製藥有限公司 呈交日期： 2025年11月5日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 01672 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | | 佔有關事件 ...

Core Insights - Company announced multiple reports at the 2025 ObesityWeek in Atlanta, Georgia, showcasing the efficacy and safety of its obesity treatment pipeline, including ASC30, ASC31, and ASC47 [1] Group 1: Clinical Research - The complete analysis of the ASC30 oral tablet in Phase Ib trials was presented [1] - A Phase Ib study of ASC30 as a monthly injection was also reported [1] - Preclinical studies on the combination of ASC31 and ASC47 were highlighted [1] Group 2: Technology and Development - The reports emphasize the promising efficacy and safety characteristics of the company's small molecules and peptides for obesity treatment [1] - The proprietary AI-assisted drug discovery platform (AISBDD) and ultra-long-acting drug development platform (ULAP) were validated through these studies [1] Group 3: Strategic Focus - The company is committed to advancing the clinical development of ASC30, ASC31, and ASC47 while engaging closely with strategic partners [1] - The goal is to better meet the treatment needs of obesity patients globally [1]

Core Insights - The announcement highlights multiple reports presented at the 2025 ObesityWeek in Atlanta, Georgia, focusing on the efficacy and safety of the company's obesity treatment pipeline [1] - The reports include a complete analysis of the ASC30 oral tablet Phase Ib study, the ASC30 monthly injection Phase Ib study, and preclinical studies of ASC31 and ASC47 combination therapy [1] - The company's proprietary technologies, including AI-assisted drug discovery and ultra-long-acting drug development platforms, are emphasized as key components of their research [1] - The CEO expresses a commitment to advancing clinical development while engaging closely with strategic partners to meet global obesity treatment needs [1]

"这些报告彰显了歌礼小分子及多肽的多元化肥胖症管线令人振奋的疗效和安全性特征，同时也印证了 歌礼专有的基于结构的AI辅助药物发现(AISBDD)和超长效药物开发平台(ULAP)的技术。"歌礼创始 人、董事会主席兼首席执行官吴劲梓博士表示，"在推进ASC30、ASC31及ASC47临床开发的同时，我 们持续聚焦与战略伙伴的紧密磋商，以确保歌礼能更好地满足全球肥胖症患者的治疗需求。" 智通财经APP讯，歌礼制药-B(01672)发布公告，在美国佐治亚州亚特兰大举行的2025年肥胖周 (ObesityWeek®)以壁报形式进行多项报告，包括ASC30每日一次口服片Ib 期研究的完整分析、ASC30每 月一次注射剂Ib期研究以及ASC31与ASC47联合用药临床前研究。 ...

Core Viewpoint - The company, Gilead Sciences-B (01672.HK), announced multiple reports to be presented at the 2025 ObesityWeek in Atlanta, Georgia, highlighting the efficacy and safety of its obesity treatment pipeline, including ASC30, ASC31, and ASC47 [1] Group 1 - The reports will include a complete analysis of the Phase Ib study of ASC30, a monthly injection study of ASC30, and preclinical studies of ASC31 and ASC47 combination therapy [1] - The presentations demonstrate the promising efficacy and safety characteristics of Gilead's small molecules and peptides in the obesity treatment pipeline [1] - The CEO, Dr. Wu Jinzi, emphasized the importance of strategic partnerships to better meet the treatment needs of global obesity patients while advancing the clinical development of ASC30, ASC31, and ASC47 [1]